MedTrace Logo

Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)

NCT00266357 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-01-14

No results posted yet for this study

Summary

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Conditions

  • Primary Insomnia

Interventions

DRUG

MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)

DRUG

Placebo / Duration of Treatment: 2 days for screening period

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2007-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00266357 on ClinicalTrials.gov